Hyodeoxycholic Acid Ameliorates Nonalcoholic Fatty Liver Disease by Inhibiting RAN-mediated PPARα Nucleus-cytoplasm Shuttling

Overview

Journal Nat Commun

Specialty Biology

Date 2023 Sep 6

PMID 37673856

Authors

Jing Zhong

Xiaofang He

Xinxin Gao

Qiaohong Liu

Yu Zhao

Ying Hong

Weize Zhu

Juan Yan

Yifan Li

Yan Li

NingNing Zheng

Yiyang Bao

Hao Wang

Junli Ma

Wenjin Huang

Zekun Liu

Yuanzhi Lyu

Xisong Ke

Wei Jia

Cen Xie

Yiyang Hu

Lili Sheng

Houkai Li

Affiliations

Soon will be listed here.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is usually characterized with disrupted bile acid (BA) homeostasis. However, the exact role of certain BA in NAFLD is poorly understood. Here we show levels of serum hyodeoxycholic acid (HDCA) decrease in both NAFLD patients and mice, as well as in liver and intestinal contents of NAFLD mice compared to their healthy counterparts. Serum HDCA is also inversely correlated with NAFLD severity. Dietary HDCA supplementation ameliorates diet-induced NAFLD in male wild type mice by activating fatty acid oxidation in hepatic peroxisome proliferator-activated receptor α (PPARα)-dependent way because the anti-NAFLD effect of HDCA is abolished in hepatocyte-specific Pparα knockout mice. Mechanistically, HDCA facilitates nuclear localization of PPARα by directly interacting with RAN protein. This interaction disrupts the formation of RAN/CRM1/PPARα nucleus-cytoplasm shuttling heterotrimer. Our results demonstrate the therapeutic potential of HDCA for NAFLD and provide new insights of BAs on regulating fatty acid metabolism.

Citing Articles

CRSP8-driven fatty acid metabolism reprogramming enhances hepatocellular carcinoma progression by inhibiting RAN-mediated PPARα nucleus-cytoplasm shuttling.

Lin Y, Liang Z, Weng Z, Liu X, Zhang F, Chong Y J Exp Clin Cancer Res. 2025; 44(1):93.

PMID: 40069732 PMC: 11895297. DOI: 10.1186/s13046-025-03329-3.

Hyodeoxycholic acid inhibits colorectal cancer proliferation through the FXR/EREG/EGFR axis.

Pang Q, Huang S, Li X, Cao J Front Cell Dev Biol. 2025; 12():1480998.

PMID: 39834394 PMC: 11743714. DOI: 10.3389/fcell.2024.1480998.

Pharmacological Mechanisms of Bile Acids Targeting the Farnesoid X Receptor.

Qi Y, Ma Y, Duan G Int J Mol Sci. 2025; 25(24.

PMID: 39769418 PMC: 11727972. DOI: 10.3390/ijms252413656.

Ramulus Mori (Sangzhi) alkaloids ameliorate high-fat diet induced obesity in rats by modulating gut microbiota and bile acid metabolism.

Shang X, Fu Y, Wang Y, Yan S Front Endocrinol (Lausanne). 2025; 15:1506430.

PMID: 39758340 PMC: 11695234. DOI: 10.3389/fendo.2024.1506430.

Gut protects against fat deposition by enhancing secondary bile acid biosynthesis.

Zha A, Qi M, Deng Y, Li H, Wang N, Wang C Imeta. 2025; 3(6):e261.

PMID: 39742294 PMC: 11683477. DOI: 10.1002/imt2.261.

References

Younossi Z . Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol. 2018; 70(3):531-544. DOI: 10.1016/j.jhep.2018.10.033. View

Folch J, Lees M, SLOANE STANLEY G . A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957; 226(1):497-509. View

Shih D, Shaposhnik Z, Meng Y, Rosales M, Wang X, Wu J . Hyodeoxycholic acid improves HDL function and inhibits atherosclerotic lesion formation in LDLR-knockout mice. FASEB J. 2013; 27(9):3805-17. PMC: 3752541. DOI: 10.1096/fj.12-223008. View

Watanabe S, Fujita K . Dietary hyodeoxycholic acid exerts hypolipidemic effects by reducing farnesoid X receptor antagonist bile acids in mouse enterohepatic tissues. Lipids. 2014; 49(10):963-73. DOI: 10.1007/s11745-014-3947-y. View

Ma J, Hong Y, Zheng N, Xie G, Lyu Y, Gu Y . Gut microbiota remodeling reverses aging-associated inflammation and dysregulation of systemic bile acid homeostasis in mice sex-specifically. Gut Microbes. 2020; 11(5):1450-1474. PMC: 7524276. DOI: 10.1080/19490976.2020.1763770. View

Regnier M, Polizzi A, Smati S, Lukowicz C, Fougerat A, Lippi Y . Hepatocyte-specific deletion of Pparα promotes NAFLD in the context of obesity. Sci Rep. 2020; 10(1):6489. PMC: 7162950. DOI: 10.1038/s41598-020-63579-3. View

Azzouzi H, Leptidis S, Bourajjaj M, Van Bilsen M, da Costa Martins P, De Windt L . MEK1 inhibits cardiac PPARα activity by direct interaction and prevents its nuclear localization. PLoS One. 2012; 7(6):e36799. PMC: 3378550. DOI: 10.1371/journal.pone.0036799. View

Sunny N, Satapati S, Fu X, He T, Mehdibeigi R, Spring-Robinson C . Progressive adaptation of hepatic ketogenesis in mice fed a high-fat diet. Am J Physiol Endocrinol Metab. 2010; 298(6):E1226-35. PMC: 2886525. DOI: 10.1152/ajpendo.00033.2010. View

Zhang X, Zhang Y, Gao W, Guo Z, Wang K, Liu S . Naringin improves lipid metabolism in a tissue-engineered liver model of NAFLD and the underlying mechanisms. Life Sci. 2021; 277:119487. DOI: 10.1016/j.lfs.2021.119487. View

10.

Deutsch E, Bandeira N, Perez-Riverol Y, Sharma V, Carver J, Mendoza L . The ProteomeXchange consortium at 10 years: 2023 update. Nucleic Acids Res. 2022; 51(D1):D1539-D1548. PMC: 9825490. DOI: 10.1093/nar/gkac1040. View

11.

Jiao N, Baker S, Chapa-Rodriguez A, Liu W, Nugent C, Tsompana M . Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD. Gut. 2017; 67(10):1881-1891. DOI: 10.1136/gutjnl-2017-314307. View

12.

Spinelli V, Lalloyer F, Baud G, Osto E, Kouach M, Daoudi M . Influence of Roux-en-Y gastric bypass on plasma bile acid profiles: a comparative study between rats, pigs and humans. Int J Obes (Lond). 2016; 40(8):1260-7. DOI: 10.1038/ijo.2016.46. View

13.

. Database Resources of the National Genomics Data Center, China National Center for Bioinformation in 2022. Nucleic Acids Res. 2021; 50(D1):D27-D38. PMC: 8728233. DOI: 10.1093/nar/gkab951. View

14.

Zheng X, Chen T, Jiang R, Zhao A, Wu Q, Kuang J . Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism. Cell Metab. 2020; 33(4):791-803.e7. DOI: 10.1016/j.cmet.2020.11.017. View

15.

Singhal A, Cohen B, MOSBACH E, Une M, Stenger R, MCSHERRY C . Prevention of cholesterol-induced gallstones by hyodeoxycholic acid in the prairie dog. J Lipid Res. 1984; 25(6):539-49. View

16.

Chen T, Ma J, Liu Y, Chen Z, Xiao N, Lu Y . iProX in 2021: connecting proteomics data sharing with big data. Nucleic Acids Res. 2021; 50(D1):D1522-D1527. PMC: 8728291. DOI: 10.1093/nar/gkab1081. View

17.

Brocker C, Patel D, Velenosi T, Kim D, Yan T, Yue J . Extrahepatic PPARα modulates fatty acid oxidation and attenuates fasting-induced hepatosteatosis in mice. J Lipid Res. 2018; 59(11):2140-2152. PMC: 6210912. DOI: 10.1194/jlr.M088419. View

18.

Chavez-Talavera O, Tailleux A, Lefebvre P, Staels B . Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease. Gastroenterology. 2017; 152(7):1679-1694.e3. DOI: 10.1053/j.gastro.2017.01.055. View

19.

Kleiner D, Brunt E, Van Natta M, Behling C, Contos M, Cummings O . Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6):1313-21. DOI: 10.1002/hep.20701. View

20.

Sehayek E, Ono J, Duncan E, Batta A, Salen G, SHEFER S . Hyodeoxycholic acid efficiently suppresses atherosclerosis formation and plasma cholesterol levels in mice. J Lipid Res. 2001; 42(8):1250-6. View